News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 17, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, 2020, at 10:00 a.m. ET
Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...
- Aug 14, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, at 10:00 a.m. ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...
- Jun 29, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today its addition to the broad-market Russell 3000® Index, the Russell 2000® Index and the...
- Jun 23, 2020Presentation Scheduled for June 25, 2020, at 11:30 a.m., ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today that Chairman and CEO Winston Black will present via webcast at the Life Sciences...
- Jun 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 02, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 14, 2020Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET
Corporate Highlights Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31,...
- May 04, 2020Accomplished Industry Executive Brings Extensive Business Development Experience and Deep Knowledge of Drug Delivery Technology to Enteris
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 30, 2020Transformative 2019 Underscored by Strong Finance Results and Enteris BioPharma Acquisition
Corporate Highlights Core specialty finance segment generated a 12.6% adjusted ROIC and yielding assets increased 4.8% year over year to $175.1 million Closed Enteris Biopharma acquisition SWK...
- Mar 26, 2020SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and...
- Feb 28, 2020Specialty Finance Portfolio Performance Highlights Strong Year, Underscored by Enteris BioPharma Acquisition and NASDAQ Uplisting
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Feb 10, 2020Accomplished Biopharmaceutical and Drug Development Executive to Lead the Expansion of Enteris' External and Internal Development Programs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 27, 2020Enteris recognized for enhancing positive image of small businesses and service to customers
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 23, 2020Trading begins today, January 23, 2020, under the ticker symbol "SWKH"
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning...
- Jan 21, 2020Trading to begin on January 23, 2020
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, today announced that its shares of common stock have been approved for listing on the...
- Jan 06, 2020A transformational 2019 positions Enteris to capitalize on potential of Peptelligence®
Acquired by SWK Holdings Corporation; Now Operating as a Wholly Owned Subsidiary Focused on Advancement of Peptelligence-Driven External Partnerships and Internal Drug Development Pipeline Entered...
- Dec 09, 2019New Hygiene Laser designed by Dental Hygienists for Dental Hygienists
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced the launch of their new Epic Hygiene laser at the Greater New York Dental Meeting, in New York City from Nov. 29 - Dec....
- Dec 06, 2019Oral KORSUVA 1 mg met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores vs. placebo after 12-week treatment period (p=0.018)
Boonton, NJ – December 6, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned...
- Dec 05, 2019
MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of...
- Dec 04, 2019
Lake Forest, Calif. – December 4, 2019 – Tenex Health, Inc., a privately held, U.S.-based medical technology company providing healthcare professionals with minimally invasive technologies to...
- Dec 02, 2019~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~
DEER PARK, Ill., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 26, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to present at the following two investor conferences in December: 8th Annual Benchmark...
- Nov 21, 2019Board Realignment Follows SWK's Acquisition of Enteris BioPharma
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that Winston Black, Chief Executive Officer of SWK, has been named...
- Nov 18, 2019
Corporate Highlights Acquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology,...
- Nov 15, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 15, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 15, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it appointed Michael DiTolla, DDS, FAGD to its board of directors, effective November 14, 2019. The appointment...
- Nov 14, 2019Biorphen® Expected to Launch by End of November
DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 13, 2019
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 08, 2019Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease
LOS ANGELES, CA – November 8, 2019 – DxTerity Diagnostics Inc. has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the...
- Nov 08, 2019Along with the release of new Longitudinal SLE Clinical Study Results, the diagnostics company announces the commercial launch of DxTerity Type 1 Interferon Testing
LOS ANGELES, CA – November 8, 2019 – DxTerity® Diagnostics Inc. has announced the results of a longitudinal clinical study with the Oklahoma Medical Research Foundation (OMRF) demonstrating...
- Nov 08, 2019—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed...
- Nov 08, 2019—New Data at ACAAI Reinforce the Need for Treatments to Reduce the Fear of Accidental Exposure to Peanut and Improve Emotional Well-Being for Adult Patients and Caregivers—
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 08, 2019— Findings Suggest that a Strong Clinical History, in Combination with Evidence of Peanut Sensitization, is the Optimal Approach to Identify Highly Sensitive Peanut-Allergic Patients —
HOUSTON--(BUSINESS WIRE)--Nov. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 07, 2019
FARMINGDALE, N.Y., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 06, 2019
DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 06, 2019--Webcast and conference call today at 4:30 p.m. ET--
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the...
- Nov 06, 2019Third Quarter Net Revenue of $8.6 Million
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.6 million for the third quarter ended September 30, 2019. Third Quarter and Recent Operating and...
- Nov 04, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today...
- Nov 04, 2019
FARMINGDALE, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and...
- Nov 01, 2019Current NATESTO® supply to the United States remains unaffected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the...
- Oct 31, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 31, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 31, 2019Recent Equity Raise and Line of Credit Provides Working Capital and Strengthened Balance Sheet to Fund Growth and Profitability
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced that it has secured a $3 million revolving line of credit from Pacific Mercantile Bank ("the Bank"), the wholly...
- Oct 30, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 30, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Oct 29, 2019
DxTerity Diagnostics has launched the IFN-1 Test for determining a systemic lupus erythematosus patient's type 1 interferon status and the risk of progressing to lupus nephritis. The firm launched...
- Oct 28, 2019
FARMINGDALE, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Oct 24, 2019
BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced the pricing of an underwritten public offering of 7,820,000 shares of its common stock at a price to the public of...
- Oct 23, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the...
- Oct 23, 2019More Than 250 Dental Professionals Attended The Event To Learn The Latest Trends And Innovations In Dentistry From Leading Industry Experts
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, hosted the inaugural Advancing Dentistry Symposium in San Diego, California Oct. 18-19. More than 250 professionals in the dental...
- Oct 22, 2019~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~
DEER PARK, Ill., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Oct 21, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced select unaudited preliminary financial results for the third quarter ended September 30, 2019. Select Preliminary...
- Oct 17, 2019NATESTO ® shown to significantly increase mean testosterone levels, while maintaining sufficient gonadotropins to preserve fertility
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO® Spermatogenesis Study as part of the “Late...
- Oct 15, 2019New Indication Allows Dentists to Remove Crowns and Veneers in Five Minutes or Less with Waterlase Dental Lasers
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is proud to announce that Waterlase dental lasers received U.S. and Canada regulatory clearance for crown and veneer removal. This...
- Oct 02, 2019— Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – — Topline Clinical Data Anticipated Fall 2019 —
MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer...
- Sep 30, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its...
- Sep 27, 2019
FARMINGDALE, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Sep 26, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 26, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Sep 25, 2019In Vitro Study Establishes Platform for Advancing Implant Technology Through Mechanobiology
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™ announced today the completion of Phase I in vitro...
- Sep 16, 2019Presentation Scheduled for Today, September 16, 2019, at 4:30 p.m., ET
Dallas, TX, September 16, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that CEO Winston Black, will...
- Sep 13, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 13, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Sep 13, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 13, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Sep 13, 2019DDS Lab will offer Keystone Dental participating dentists exceptional quality, service and value on dental laboratory implants, products and services.
DDS Lab and Keystone Dental have formed a strategic alliance to offer the national dental implant supplier's participating dentists discounted pricing on dental lab implants, products and...
- Sep 06, 2019
Dallas, TX, September 6, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...
- Sep 03, 2019
DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Sep 03, 2019SWK Expands Board of Directors to Meet NASDAQ Listing Requirements
Dallas, TX – September 3, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today that the Company has...
- Aug 28, 2019
MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 28, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 28, 2019Company expands implant portfolio with the addition of the Cervical Spine Truss System - Stand-Alone
4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™, announced today that the company has received 510(k)...
- Aug 28, 2019BIOLASE to Participate at Dougherty & Company Institutional Investor Conference on September 5, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate at the 4th Annual Dougherty & Company Institutional Investor Conference being...
- Aug 27, 2019
MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 27, 2019SWK Holdings Corporation acquires 100% of Enteris’ equity
Dallas, TX and Boonton, NJ – August 27, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, and Enteris BioPharma,...
- Aug 21, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 21, 2019Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™
Boonton, NJ – August 21, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today...
- Aug 19, 2019ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation
DEER PARK, Ill.--(BUSINESS WIRE)--Aug. 19, 2019-- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products...
- Aug 14, 2019
FARMINGDALE, N.Y., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 12, 2019Total revenues of $5.7 million for the second quarter 2019 compared to $6.8 million for the second quarter 2018.
Dallas, TX, August 12, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2019 financial...
- Aug 12, 2019
FARMINGDALE, N.Y., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 08, 2019Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN for BPH and NDA Submission Expected in Summer 2020 Company to Host Investor Conference Call on Thursday, August 8, 2019, 8 a.m. ET
MIAMI, Aug. 08, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 08, 2019--Webcast and conference call today at 4:30 p.m. ET --
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 08, 2019Second Quarter Gross Margin Increased Almost 370 Basis Points Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $8.7 million for the second quarter ended June 30, 2019, a decrease of 29% compared to the second...
- Aug 07, 2019
FARMINGDALE, N.Y., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Aug 07, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period...
- Aug 06, 2019ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019
DEER PARK, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 06, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 05, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2019 financial and operating results on Thursday, August 8, 2019 after the...
- Aug 02, 2019U.S. market not affected
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will voluntarily replace certain NATESTO® lots released in the Canadian and South...
- Aug 01, 2019
MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Aug 01, 2019-ET-105 assigned Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020
DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Aug 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Aug 01, 2019Final study results accepted for “Late Breaking Presentation” on October 16, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the NATESTO® Spermatogenesis Study results have been accepted for presentation as a...
- Jul 30, 2019
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 30, 2019Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The...
- Jul 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the...
- Jul 24, 2019NATESTO® Now Covered on Payer Plans Covering Over 6 Million U.S. Lives
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced today that NATESTO® (testosterone nasal gel) is now on formulary...
- Jul 19, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated...
- Jul 18, 2019
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jul 18, 2019
FARMINGDALE, N.Y., July 18, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jul 12, 2019
DEER PARK, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jul 11, 2019Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community
BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders...